Cspc Innovation Pharmaceutical Stock Beta
| 300765 Stock | 28.62 0.08 0.28% |
CSPC Innovation Pharmaceutical fundamentals help investors to digest information that contributes to CSPC Innovation's financial success or failures. It also enables traders to predict the movement of CSPC Stock. The fundamental analysis module provides a way to measure CSPC Innovation's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CSPC Innovation stock.
CSPC | Beta |
CSPC Innovation Pharmaceutical Company Beta Analysis
CSPC Innovation's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current CSPC Innovation Beta | -0.14 |
Most of CSPC Innovation's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CSPC Innovation Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, CSPC Innovation Pharmaceutical has a Beta of -0.145. This is 111.79% lower than that of the Food Products sector and 113.06% lower than that of the Consumer Staples industry. The beta for all China stocks is 3.33% lower than that of the firm.
CSPC Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CSPC Innovation's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CSPC Innovation could also be used in its relative valuation, which is a method of valuing CSPC Innovation by comparing valuation metrics of similar companies.CSPC Innovation is currently under evaluation in beta category among its peers.
As returns on the market increase, returns on owning CSPC Innovation are expected to decrease at a much lower rate. During the bear market, CSPC Innovation is likely to outperform the market.
CSPC Fundamentals
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0603 | ||||
| Profit Margin | 0.25 % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 38.91 B | ||||
| Shares Outstanding | 1.4 B | ||||
| Shares Owned By Insiders | 76.86 % | ||||
| Shares Owned By Institutions | 6.38 % | ||||
| Price To Book | 10.54 X | ||||
| Price To Sales | 19.67 X | ||||
| Revenue | 2.5 B | ||||
| Gross Profit | 844.52 M | ||||
| EBITDA | 654.85 M | ||||
| Net Income | 755.56 M | ||||
| Total Debt | 544.96 M | ||||
| Book Value Per Share | 2.74 X | ||||
| Cash Flow From Operations | 927.24 M | ||||
| Earnings Per Share | 0.37 X | ||||
| Target Price | 41.96 | ||||
| Number Of Employees | 1.89 K | ||||
| Beta | -0.14 | ||||
| Market Capitalization | 40.2 B | ||||
| Total Asset | 5.63 B | ||||
| Retained Earnings | 2.55 B | ||||
| Working Capital | 3.71 B | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 5.63 B | ||||
| Last Dividend Paid | 0.27 |
About CSPC Innovation Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CSPC Innovation Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CSPC Innovation using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CSPC Innovation Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in CSPC Stock
CSPC Innovation financial ratios help investors to determine whether CSPC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CSPC with respect to the benefits of owning CSPC Innovation security.